Featured at ASCP “Effects of Lemborexant on Sleep Architecture in Adults and Elderly Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease”

2024-06-15T09:13:21-04:00May 31st, 2024|

Effects of Lemborexant On Sleep Architecture in Adults and Elderly Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease.Gary Zammit, President and CEO of Clinilabs Drug Development Corporation, was at the ASCP conference in Miami Beach in May, where Dr. Zammit and the team at Eisai Inc. discussed the “Effect of Lemborexant on Sleep Architecture in Adults and Elderly Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease,” presented on Poster #59.

Share This Story, Choose Your Platform!

Go to Top